Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Muscle-Invasive Bladder Carcinoma: early-phase trial registry
12 of 15 indexed Muscle-Invasive Bladder Carcinoma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #1,140 of 28,707 conditions by registered trial count.
15 US clinical trials · 12 currently recruiting · #1,140 of 28,707 conditions by registered trial count
Muscle-Invasive Bladder Carcinoma: 15 US clinical trials tracked, 12 recruiting.
Muscle-Invasive Bladder Carcinoma is the subject of 15 registered US clinical trials on ClinicalTrials.gov, 12 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 12 in Phase 1-2 (earlier-stage). The most active sponsor is Shilpa Gupta, MD, running 1 of these trials.
Enrollment posture brief
Registry condition muscle-invasive-bladder-carcinoma
OPEN 12 | RECR 80% | LATE 1 | EARLY 12 | RANK #1140 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Ablation (80% recruiting · 5 trials)
Muscle-Invasive Bladder Carcinoma lists 12 open slots (80% of 15 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Muscle-Invasive Bladder Carcinoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Muscle-Invasive Bladder Carcinoma is recruiting above its size-band peers.
12 of 15 indexed trials (80%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Muscle-Invasive Bladder Carcinoma trials is spread across many organizations.
Shilpa Gupta, MD accounts for 1 of 15 trials (6.7%). 15 distinct sponsors appear on at least one study for this condition label.
-
Most Muscle-Invasive Bladder Carcinoma trials plan to enrol fewer than 100 people.
Median target enrolment is 40 among the 15 trials that report a genuine target (sentinel values excluded). 12 of those (80%) plan for fewer than 100 participants.
-
Muscle-Invasive Bladder Carcinoma research is mostly interventional.
15 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
15 total, page 1 of 1
Modular Trial of sEphB4-HSA in EphrinB2-High Solid Tumors
Vasgene Therapeutics
NCT06493552
Prophylactic Antibiotics in Cystectomy With Diversion
University of Minnesota
NCT06190197
Clinical Trial to Evaluate Post-Operative Outcomes of Ureteral Stent vs Ureteral Stent Free Radical Cystectomy
Thomas Jefferson University
NCT07234968
Enfortumab Vedotin and Pembrolizumab Combined With Radiotherapy in Muscle Invasive Bladder Cancer
University of California, San Francisco
NCT06470282
Partial Cystectomy & Extended Pelvic Lymph Node Dissection With SOC Perioperative Systemic Therapy
Case Comprehensive Cancer Center
NCT06290687
Gemcitabine/Cisplatin Plus Cemiplimab With or Without Fianlimab in Localized Muscle-invasive Bladder Cancer (NeoSTOP-IT)
Columbia University
NCT06571708
Personalized Cancer Vaccine (PCV) Strategy in Patients With Solid Tumors and Molecular Residual Disease
Washington University School of Medicine
NCT06529822
Pre-Habilitation with Mindfulness and Exercise for Patients Undergoing Radical Cystectomy (PRIMER Trial)
University of Virginia
NCT05790850
Futibatinib in Combination With Durvalumab Prior to Cystectomy for the Treatment of Muscle-Invasive Bladder Cancer Patients Who Are Ineligible for Cisplatin-based Therapy
Yuanquan Yang
NCT06263153
Bladder Preservation for Patients With Muscle Invasive Bladder Cancer (MIBC) With Variant Histology
Leslie Ballas
NCT06417190
Adaptive RADiation Therapy With Concurrent Sacituzumab Govitecan (SG) for Muscle Invasive Bladder Cancer
Shilpa Gupta, MD
NCT05833867
Sacituzumab Govitecan Before Radical Cystectomy for the Treatment of Non-Urothelial Muscle Invasive Bladder Cancer
University of Washington
NCT05581589
Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer
National Cancer Institute (NCI)
NCT03775265
A Study of Risk Enabled Therapy After Neoadjuvant Immunochemotherapy for Bladder Cancer
Fox Chase Cancer Center
NCT04506554
Pembrolizumab in Muscle-invasive Bladder Cancer
Matthew Galsky
NCT05406713
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 4 |
| Phase 2 | 8 |
| Phase 3 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Muscle-Invasive Bladder Carcinoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Muscle-Invasive Bladder Carcinoma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Muscle-Invasive Bladder Carcinoma page
15 registered trials, 12 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 12 Muscle-Invasive Bladder Carcinoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Shilpa Gupta, MD sponsors the most Muscle-Invasive Bladder Carcinoma trials on record, review their full trial history before evaluating a specific study. See Shilpa Gupta, MD's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Muscle-Invasive Bladder Carcinoma condition card totals 15 registered trials; most-linked intervention Cisplatin; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.